Heme oxygenase-1 genotype and restenosis after balloon angioplasty: A novel vascular protective factor

Journal of the American College of Cardiology

Volumn 43, Issue 6, 2004, Pages 950-957

  Schillinger, Martin ^a   Exner, Markus ^b   Minar, Erich ^a   Mlekusch, Wolfgang ^a   Müllner, Marcus ^a   Mannhalter, Christine ^b   Bach, Fritz H ^c   Wagner, Oswald ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

C reactive protein; Carbon monoxide; CI; CO; Confidence interval; CRP; GT; Guanosine thymidine; Heme oxygenase 1; HO 1; Interquartile range (range from the 25th to the 75th percentile); IQR; PAD; Peak systolic velocity; Peripheral artery disease; PSV; PTA

Indexed keywords

HEME OXYGENASE 1; PROTECTIVE AGENT;

ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; FEMALE; FEMOROPOPLITEAL BYPASS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REDUCTION; RESTENOSIS; RISK FACTOR; STENT; UPREGULATION;

AGED; ANGIOPLASTY, BALLOON; AUSTRIA; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; FEMALE; GENOTYPE; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; HUMANS; MALE; MASSACHUSETTS; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 1542499475     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.09.058     Document Type: Article

References (46)

1. Dormandy J.A., Rutherford B. Management of peripheral arterial disease (PAD) TASC working group TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 31:2000;S1-296.
2. Kastrati A., Dirschinger J., Schomig A. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz. 25:2000;34-46.
3. Bauters C., Lamblin N., Amouyel P. Gene polymorphisms and outcome after coronary angioplasty. Curr Interv Cardiol Rep. 3:2001;281-286.
4. Roguin A., Hochberg I., Nikolsky E., et al. Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 87:2001;330-332.
5. Jukema J.W., Kastelein J.J. Tailored therapy to fit individual profiles genetics and coronary artery disease. Ann NY Acad Sci. 902:2000;17-24.
6. Tulis D.A., Durante W., Peyton K.J., Evans A.J., Schafer A.I. Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. Atherosclerosis. 155:2001;113-122.
7. Exner M., Schillinger M., Minar E., et al. Heme oxygenase-1 microsatellite gene promoter polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther. 8:2001;433-440.
8. Duckers H.J., Boehm M., True A.L., et al. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med. 7:2001;693-698.
9. Ishikawa K., Sugawara D., Wang X.P., et al. Heme oxygenase-1 inhibits atherosclerotic lesion formation in LDL-receptor knockout mice. Circ Res. 88:2001;506-512.
10. Maines M.D. Heme oxygenase function, multiplicity, regulatory mechanisms and clinical application. FASEB J. 2:1988;2557-2568.
11. Tenhunen R., Marver H.S., Schmid R. Microsomal heme oxygenase characterization of the enzyme. J Biol Chem. 244:1969;6388-6394.
12. Orford J.L., Selwyn A.P., Ganz P., Popma J.J., Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol. 86:2000;6H-11H.
13. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126.
14. O'Brian E.R., Schwartz S.M. Update of the biology and clinical study of restenosis. Trends Cardiovasc Med. 4:1994;169-178.
15. Kimpara T., Takeda A., Watanabe K., et al. Microsatellite polymorphism in the human heme oxygenase-1 gene promotor and its application in association studies with Alzheimer and Parkinson disease. Hum Genet. 100:1997;145-147.
16. Yamada N., Yamaya M., Okinaga S., et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet. 66:2000;187-195.
17. Minar E., Pokrajac B., Ahmadi R., et al. Brachytherapy for prophylaxis of restenosis after long-segment femoropopliteal angioplasty pilot study. Radiology. 208:1998;173-179.
18. Ranke C., Creutzig A., Alexander K. Duplex scanning of the peripheral arteries correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 18:1992;433-440.
19. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1997.
20. Zhang J., Yu K.F. What's the relative risk? A method for correcting the odds ratio in cohort studies of common outcomes. JAMA. 280:1998;1690-1691.
21. Otterbein L.E., Bach F.H., Alam J., et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med. 6:2000;422-428.
22. Togane Y., Morita T., Suematsu M., Ishimura Y., Yamazaki J.I., Katayama S. Protective role of endogenous carbon monoxide in neointimal development elicited by arterial injury. Am J Physiol. 278:2000;H623-632.
23. Morita T., Kourembanas S. Endothelial expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J Clin Invest. 96:1995;2676-2682.
24. Morita T., Mitsialis S.A., Liu Y., Kourembanas S. Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. J Biol Chem. 52:1997;32804-32809.
25. Yachie A., Niida Y., Wada T., et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest. 103:1999;129-135.
26. Schillinger M., Exner M., Mlekusch W., et al. Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther. 9:2002;59-66.
27. Liuzzo G., Buffon A., Biasucci L.M., et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 98:1998;2370-2376.
28. Gottsauner-Wolf M., Zasmeta G., Hornykewycz S., et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 21:2000;1152-1158.
29. Virmani R., Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol. 10:1999;499-506.
30. Farb A., Sangiorgi G., Carter A.J., et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 99:1999;44-52.
31. Pepys M.B. The acute phase response and C-reactive protein. Weatherall D.J., Ledingham J.G.G., Warrell D.A. Oxford Textbook of Medicine. 3rd edition:1995;1527-1533 Oxford University Press, Oxford.
32. Schillinger M., Exner M., Mlekusch W., et al. Vascular inflammation after femoropopliteal PTA potential impact on restenosis. Radiology. 225:2002;21-26.
33. Leung D.Y., Glagov S., Mathews N.B. Cyclic stretching stimulates synthesis of matrix components by arterial smooth muscle cells in vitro. Science. 191:1976;475-477.
34. Bach F.H., Hancock W.W., Ferran C. Protective genes expressed in endothelial cells a regulatory response to injury. Immunol Today. 18:1997;483-486.
35. Bach F.H., Ferran C., Candinas D., et al. Accomodation of xenografts expression of "protective genes" in endothelial and smooth muscle cells. Transplant Proc. 29:1997;56-58.
36. Okinaga S., Takahashi K., Takeda K., et al. Regulation of human heme oxygenase-1 gene expression under thermal stress. Blood. 87:1996;5074-5084.
37. Chen Y.H., Lin S.J., Lin M.W., et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet. 111:2002;1-8.
38. Otterbein L.E., Zuckerbraun B.S., Haga M., et al. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med. 9:2003;183-190.
39. Virmani R., Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol. 10:1999;499-506.
40. Farb A., Sangiorgi G., Carter A.J., et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 99:1999;44-52.
41. Minar E., Pokrajac B., Maca T., et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty results of a prospective randomized study. Circulation. 102:2000;2694-2699.
42. Suzuki T., Kopia G., Hayashi S., et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 104:2001;1188-1193.
43. Sousa J.E., Costa M.A., Abozaid A.C., et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents one year angiographic and intravascular ultrasound follow-up. Circulation. 104:2001;2007-2011.
44. Melo L.G., Agrawal R., Zhang L., et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation. 105:2002;602-607.
45. Liu X.M., Chapman G.B., Wang H., et al. Adenovirus-mediated heme oxygenase-1 gene expression stimulates apoptosis in vascular smooth muscle cells. Circulation. 105:2002;79-84.
46. Baranano D.E., Rao M., Ferris C.D., et al. Biliverdin reductase a major physiologic cytoprotectant. Proc Natl Acad Sci USA. 99:2002;16093-16098.